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Integration of reverse transcribed retroviral cDNA is not restricted to particular host DNA sequences. However, the
frequency of integration into a particular phosphodiester bond is influenced by the local sequence. Here we examine the
target-sequence preferences of purified HIV integrase and viral nucleoprotein complexes (preintegration complexes) isolated
from freshly infected cells. We find that the three-base sequence including the integration site is not the major factor
determining the frequency of integration, since identical triplets embedded in different sequences are used with very different
efficiencies. However, there is a statistically significant bias against integration upstream of a pyrimidine nucleotide. The
target-sequence preferences of purified integrase and preintegration complexes are very different. Strong integration sites
on opposite DNA strands occur in pairs separated by five residues when preintegration complexes are used but not with
purified integrase. These studies highlight the difference between the two sources of HIV integration activity and may
provide the basis for a simple assay for the correct assembly of viral nucleoprotein complexes. q 1996 Academic Press, Inc.
Integration of reverse transcribed retroviral cDNA into Several previous studies have exploited the in vitro
integration systems to characterize the factors influenc-a chromosome of the host is a necessary step in retrovi-
ral replication. Integration is dependent on a viral-en- ing the choice of integration target sites. Sites in naked
DNA are used with different efficiencies, though integra-coded integrase protein (7, 11, 26, 32) and specific DNA
sequences at each end of an unintegrated viral DNA (9, tion at most sites is detectable (5, 10, 19, 22). In two
studies of integration by simple retroviruses in vitro,26, 31). During integration in vivo, the blunt ends of the
linear product of reverse transcription are first cleaved MoMLV and ALV, the integration sites selected by puri-
fied integrase were similar to the sites selected by prein-to remove two nucleotides from each 3*-end. The re-
cessed 3* ends are then joined to protruding 5* ends of tegration complexes (21, 30).
Here we characterize the DNA sequence prefer-breaks made in the target DNA. For the case of HIV, the
points of joining on the two DNA strands are staggered ences of HIV-1 integration complexes in detail and
by five bases in the 5* direction. This intermediate is then compare integration by purified HIV-1 integrase and
processed, probably by host DNA repair enzymes, to HIV-1 preintegration complexes. In assays using puri-
yield an integrated provirus (see 14 for a review). fied integrase, a short duplex oligonucleotide matching
In reconstituted reactions in vitro, purified integ- one end of the unintegrated viral DNA (LTR) was used
rases can cleave two nucleotides from the 3* end of a as the integration donor DNA. In assays with preinte-
DNA substrate that resembles the viral end and direct gration complexes, endogenously synthesized HIV
covalent integration of the cleaved products into a tar- cDNA served as the donor.
get DNA (4, 6, 10, 19, 20, 33, 37). In vivo, integrase An oligonucleotide containing all possible three-base
proteins and the viral DNAs are found in large nucleo- DNA sequences (triplet target) was designed to serve
protein complexes called preintegration complexes. as an integration target (Table 1). We chose three base
Such complexes have been partially purified from cells sequences because these are the longest that can be
infected with Moloney murine leukemia virus (MoMLV), completely characterized with reasonable effort. Thirty-
Avian leukosis virus (ALV), or Human immunodefi- two different trinucleotide sequences are encoded in the
ciency virus (HIV) (2, 13, 15, 23). These preintegration top strand and the remaining 32 are encoded in the bot-
complexes are capable of directing the covalent con- tom strand. Triplets are overlapped and embedded in
nection of the endogenously synthesized retroviral this 34-base pair segment without duplication. The triplet
DNA into a target DNA added in vitro. target oligonucleotide was cloned into a plasmid DNA
for use as an integration target. Integration into flanking
DNA sequences was also analyzed for both purified in-1 To whom correspondence and reprint requests should be ad-
dressed. tegrase and preintegration complexes. Furthermore, inte-
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the gel corresponded to integration at a specific phos-
phodiester bond. The frequency of integration at a partic-
ular site was reflected in the intensity of the correspond-
ing band on the final autoradiogram. PCR primers to
either side of the cloned triplet target were used to assay
integration into each target DNA strand.
We included an ‘‘EDTA control’’ in each series of exper-
iments. EDTA is known to suppress integration by chelat-
ing essential metal ions. We confirmed that no PCR am-
plification products were found if EDTA was included in
the integration reaction buffer. This shows that the bands
we observed when EDTA was omitted are due to integra-
tion products and not to amplification from unreacted
substrate DNAs.
Figures 2A and 2B present the results of the PCR assay
of integration sites in the triplet target. Integration into
the top and bottom strands is illustrated in A and phos-
phorimager quantitation of the data is illustrated in B. It
can be seen that the intensities of different bands vary
over at least a 10-fold range.
Table 2 summarizes the intensity of integration brought
about by purified integrase at each triplet in the all-triplet
target. Additional data on utilization of triplets in flanking
sequences and in another plasmid is also included. The
5' AGACTACGAAATCAACAGCACCCTCCGCCATAAG 3'
3' TCTGATGCTTTAGTTGTCGTGGGAGGCGGTATTC 5'
64 Top
64 Bottom
5' AACAGCTATGACCATG 3'
5' GTAAAACGACGGCCAGT 3'
1201 (top strand)
1211 (bottom strand)
Integration target containing all triplet sequences
PCR primers (target DNA)
5' ACTGCTAGAGATTTTCCACACGGATCCTAGGC 3'
3'ACGATCTCTAAAAGGTGTGCCTAGGATCCG 5'
FB64
FB65-2
Viral cDNA end mimic
TABLE 1
Sequences of DNA Oligonucleotides Used in This Study
5' GCCTAGGATCCGTGTGGAAAATC 3'
5' TGTGAATTAGCCCTTCCA 3'
5' TGTGGAAAATCTCTAGCA 3'
FB66
FB642 (U3)
FB652 (U5)
PCR primers (viral end)
Note. The 64 possible DNA triplet sequences in the all-triplet target 
(bottom) are marked with brackets. integration sites for each triplet lay between the first and
second nucleotide (i.e., 5*-N*NN-3*, where * marks the
integration site). Triplet sequences are marked as hotgration into a second plasmid target was analyzed for
(500 arbitrary units), medium (100–500 units), or coldpurified integrase.
(100 units) for integration frequency. The data in TableThe integration products were analyzed by a PCR
2 show that integration frequency is not strongly corre-method (Fig. 1) (3, 21, 30). Following integration in vitro,
lated with the triplet sequence. For example, the fre-products were deproteinized and used as templates for
quently occurring sequence AAT is hot in one case, me-PCR amplification. PCR primers were selected so that
dium in seven cases, and cold in three cases.one primer was complementary to a target DNA se-
The results of the PCR assay of integration broughtquence, and the other was complementary to the LTR
about by preintegration complexes are also illustrated interminus. The target primer was 32P-labeled on its 5* end.
Fig. 2. Integration into the triplet target and additionalPCR amplification of integration products generated a
flanking sequences was studied. The results of thesepopulation of molecules that were then denatured and
analyzed on a DNA sequencing-type gel. Each band on experiments are summarized in Table 3. Sequences
FIG. 1. PCR method for analyzing integration sites. Binding sites for primers used to amplify integration products are shown as grey rectangles.
The diagram shows the method used for analysis of integration directed by purified integrase. A duplex oligonucleotide served as the donor DNA,
and a circular plasmid as the target DNA. The method for analyzing integration directed by preintegration complexes is conceptually similar, but a
10-kb viral cDNA served as the integration donor and an isolated restriction fragment served as target. A plasmid containing all possible DNA
sequence triplets (pLOUC, referred to here as ‘‘the triplet target’’) was constructed in two steps. Oligonucleotides 64 top and 64 bottom (Table 1)
were annealed and ligated with pBS-SK/ that had been cleaved with EcoRV. Plasmids containing the desired insert (pLO) were isolated. DNA from
this plasmid was found to give high backgrounds when used as an integration target in some PCR assays (described below), so the insert was
recloned into the smaller plasmid pUC19. To accomplish this, a DNA fragment containing the cloned insert was isolated from pLO DNA by cleavage
with EcoRI and HindIII and ligated with pUC19 DNA cleaved with EcoRI and HindIII, yielding plasmid pLOUC DNA.
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FIG. 2. Sites of integration used by purified HIV-1 integrase or preintegration complexes on the all triplet target. (A) Pattern of favored and disfavored
sites for integration on the two DNA strands. For preintegration complexes, the U3 primer FB642 was used for the top strand and the U5 primer FB652
was used for the bottom strand. (B) Phosphorimager quantitation of the gel lanes in A. (C) Integration carried out by purified integrase in the presence
of Mn2/ and Mg2/. Integration was assayed by PCR into phage lambda target DNA as described (3, 24). In the integration assay using purified
integrase, a duplex oligonucleotide, FB64/65-2 (Table 1), resembling the U5 viral end was used. 0.03 mM of FB64/65-2 was incubated with 0.26 mg of
purified integrase (IN) for 10 min at 377 in integration buffer (5 mM MnCl2 , 20 mM HEPES (pH 7.0), 10 mM 2-mercaptoethanol, 10% (v/v) glycerol, 0.1
mg/ml bovine serum albumin), resulting in the stable assembly of integrase with the LTR DNA (12). The target DNA (final concentration 0.028 mM)
was then added to the reaction to give a total volume of 20 ml. Reactions were incubated for a further 50 min at 377 and then stopped by adding 1
ml of 0.5 M EDTA and 1 ml of 0.1% SDS. The products were purified by phenolchloroform extraction and ethanol precipitation and then redissolved in
20 ml of TE. 2 ml of the integration product were used as template for the PCR amplification. Two plasmids were used as integration targets: pLOUC
and pUC19(WT) (described in 1). Preintegration complexes were prepared as described and partially purified by sucrose gradient centrifugation (15,
24). In the integration assay, 11 nM of DNA target (a PvuII restriction fragment released from pLOUC containing the triplet target) was added to
cytoplasmic extracts containing preintegration complexes in Buffer K. Reactions were incubated for 1 hr at 377. The reaction was then stopped and
the products purified as described (24). The integration products were dissolved in 20 ml of TE. 2 ml of this solution were used as template for PCR
amplification. Integration products were analyzed by PCR essentially as described (3, 21, 30). Each integration product was assayed in two separate
reactions containing either primer 1201 or 1211 from New England Biolabs as the target primer. Products of reactions with purified integrase were
amplified with primer FB66 (viral end primer). Products of reactions with preintegration complexes were amplified with viral end primers FB652 (U5)
or FB642 (U3) (Table 1). To visualize the amplification product, one primer was labeled. Control experiments revealed that similar results were obtained
whether the target primer or the LTR primer was labeled. The molecular lengths of PCR products were determined by electrophoresis in lanes adjacent
to size markers generated by Sanger DNA sequencing reactions. The hotspots in Tables 2 and 3 were catalogued by visual inspection, guided by
Phosphorimager traces (quantitation based on Phosphorimager traces alone at times conflicted with the relative strengths of signals as judged by
autoradiography due to inadequate resolution of weak bands adjacent to strong ones by the Phosphorimager).
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TABLE 2
Analysis of Target Sites Used by Purified Integrase in the All-Triplet Target and Another Target
H M C H M C H M C H M C
TTT 3 3 TCT 1 1 TAT 1 1 TGT 1 1
TTC 3 1 TCC 1 TAC 2 TGC 6
TTA 4 2 TCA 4 1 TAA 2 4 TGA 1 2
TTG 1 6 1 TCG 3 TAG 1 TGG 1 1
CTT 5 2 CTT 1 1 CAT 1 1 CGT 3
CTC 1 CCC 1 CAC 1 1 1 CGC 1 1
CTA 1 1 CCA 3 CAA 7 1 CGA 4 1
CTG 1 CCG 1 CAG 2 CGG 1 1
ATT 4 2 ACT 1 AAT 1 7 3 AGT 1 1
ATC 1 2 ACC 1 AAC 1 2 1 AGC 5 1
ATA 2 ACA 1 1 AAA 1 6 1 AGA 1 1
ATG 1 1 ACG 5 AAG 1 4 1 AGG 1
GTT 1 3 GCT 5 GAT 1 1 1 GGT 1
GTC 1 GCC 3 GAC 1 1 GGC 3 1
GTA 2 1 GCA 4 1 GAA 1 2 2 GGA 1
GTG 2 GCG 2 1 GAG 1 GGG 1
Note. H, hot; M, medium; C, cold. Integration at a specific triplet as described here indicates covalent joining 5* of the second nucleotide in the
triplet sequence.
were scored hot (25 units), medium (10 to 25 units), or the two types of integration complexes, integration by
both was less frequent upstream of pyrimidine residues.cold (10 units). As we found for purified integrase, the
efficiency of integration into triplet sequences was This can be seen by comparing the left two columns with
the right two columns in Tables 2 and 3. The bias wasstrongly dependent on the context of the triplet, since no
clear relationship between triplet sequence and integra- found to be significant for both tables (P values of0.001
for Table 2 and 0.0188 for Table 3 by Fisher’s Exacttion frequency was found. Comparison of the integration
pattern generated by purified integrase to that generated test).
Several further experiments were carried out to ex-by preintegration complexes reveals that the two are
quite different. clude possible artifacts. Multiple aliquots from the same
integration reaction were amplified separately andAlthough the patterns of integration were different for
TABLE 3
Analysis of Target Sites Used by Partially Purified Preintegration Complexes in the All-Triplet Target and Flanking Sequences
H M C H M C H M C H M C
TTT 1 TCT 1 TAT 1 TGT 1
TTC 3 TCC 1 TAC 1 TGC 1
TTA 1 1 TCA 2 TAA 2 TGA 1
TTG 2 TCG 1 1 TAG 1 2 TGG 2
CTT 2 CTT 1 CAT 1 CGT 2
CTC 1 CCC 1 CAC 1 CGC 1
CTA 2 CCA 1 CAA 2 CGA 2 1
CTG 1 CCG 1 CAG 1 CGG 1
ATT 2 ACT 1 1 AAT 3 AGT 1 1
ATC 2 ACC 1 AAC 2 2 AGC 2
ATA 1 1 ACA 1 AAA 1 AGA 2
ATG 1 ACG 2 AAG 1 1 AGG 1
GTT 2 1 GCT 2 GAT 1 1 GGT 1
GTC 1 GCC 1 GAC 1 GGC 1 1
GTA 1 GCA 1 1 GAA 1 2 1 GGA 1
GTG 1 GCG 1 1 GAG 1 GGG 1
Note. Markings are the same as in Table 2.
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FIG. 3. Prominent sites of integration mapped on the triplet target sequence. (A) Sites used by preintegration complexes. The dotted lines indicate
the linkage between integration sites on each DNA strand. (B) Sites used by purified integrase. Arrows mark the locations of prominent hotspots.
The grey rectangles mark the all triplet target sequence.
shown to yield very similar gel patterns (data not shown). complexes and Mn2/ in reactions with HIV-1 integrase.
We do not believe this substitution is significant becauseThus the presence of hotspots and cold spots could not
be a statistical artifact brought about by the amplification purified integrase shows similar target-site preference
with the two metal ions. Figure 3C presents a comparisonof very small numbers of integration products. Integration
patterns for preintegration complexes in crude extracts of integration into a well studied region of the lambda
DNA chromosome carried out by purified HIV-1 integrasewere compared with those for complexes that had been
partially purified by sucrose gradient sedimentation. The in the presence of Mn2/ or Mg2/. While slight differences
can be seen, the overall pattern of hot and cold spots ispatterns generated were found to be closely similar, indi-
cating that partial purification of preintegration com- generally similar.
Information on integration site preferences is availableplexes did not influence site selection (data not shown).
The unintegrated HIV cDNA contains two different ter- for three other integration systems, those of MoMLV,
ALV, and the yeast retrotransposon Ty1. Retrotransposi-minal sequences, U3 and U5. Similar patterns of integra-
tion sites were seen regardless of whether the U5-spe- tion by the Ty elements is carried out by reverse tran-
scriptase and integrase enzymes similar in function andcific or U3-specific primer was used for the analysis (data
not shown). This finding confirms that the sequences of sequence to those of retroviruses. Ty1 integration is dis-
favored 5* of T residues (18). MoMLV integration is fa-the primers used for amplification do not influence the
resulting pattern of amplification products. This experi- vored 3* of the sequence 5*-TpN-3* (28), but no bias of
the base 5* of the point of joining was reported. ALVment also shows that the two cDNA ends in the preinte-
gration complex are functionally equivalent with respect integration is favored 5* of G or C residues (16). Here
we report that HIV integration is favored 5* of a purineto target DNA recognition.
During normal integration of HIV in vivo the ligation residue. Sequences of integration sites used by HIV-1 in
vivo, although few in number, also display more frequentjunctions of the two viral DNA ends are inferred to be
separated by 5 bp. Integration at a particular point on joining 5* of a purine residue (34–36) (S. Carteau and F.
D. B., unpublished data). Evidently HIV, MoMLV, ALV, andone strand should therefore be correlated with integra-
tion into the other strand at a separation of 5 bp. Charac- Ty1, each have distinct target sequence preferences.
Previous comparisons of integration by purified integ-terization of the products of reactions in vitro with HIV-1
preintegration complexes confirms this expectation (13) rase and by preintegration complexes from simple retrov-
iruses have established that the two sources of integra-(C. Farnet, personal communication). Figure 3A presents
a map of prominent integration sites used by preintegra- tion activity exhibit similar target-site preferences. This
was true for integration by MoMLV into naked DNA, pro-tion complexes in the triplet target. Most hotspots are
matched by hotspots in the expected position 5 base tein DNA complexes, and minichromosomes. In each
case only minor differences in the patterns of integrationpairs away on the opposite strand. For unknown reasons
one site displayed a 4-bp spacing and another a 6-bp were detected (29, 30). In the case of ALV, purified integ-
rase and preintegration complexes again showed similarspacing. Our findings confirm that preintegration com-
plexes in vitro direct coupled integration by the two ends but not identical target-site preferences (21). In our exper-
iments the target-site preferences of purified integraseof the viral cDNA. No similar correlation of integration
sites on the two strands was observed in experiments and preintegration complexes of HIV are essentially un-
correlated. In this respect, therefore, HIV differs funda-using purified integrase (Fig. 3B).
We used Mg2/ in reactions containing preintegration mentally from MoMLV and ALV.
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11. Donehower, L. A., and Varmus, H. E., Proc. Natl. Acad. Sci. USAHIV preintegration complexes carry out coordinated
81, 6461–6465 (1984).integration of the two ends of the viral DNA (13, 15),
12. Ellison, V., and Brown, P. O., Proc. Natl. Acad. Sci. USA 91, 7316–
while purified integrase incorporates viral ends (almost) 7320 (1994).
independently of each other (5, 6). Perhaps the con- 13. Ellison, V. H., Abrams, H., Roe, T., Lifson, J., and Brown, P. O., J.
Virol. 64, 2711–2715 (1990).straints needed to hold the viral ends together during
14. Farnet, C. M., and Bushman, F. D., AIDS 10, S3–S11 (1996).integration influence target site selection. It may be rele-
15. Farnet, C. M., and Haseltine, W. A., Proc. Natl. Acad. Sci. USA 87,vant that purified integrases from ALV and MoMLV are
4164–4168 (1990).
more efficient than purified HIV integrase in bringing 16. Fitzgerald, M. L., and Grandgenett, D. P., J. Virol. 68, 4314–4321
about coupled insertions of viral ends (4, 17, 19). Per- (1994).
17. Fitzgerald, M. L., Vora, A. C., Zeh, W. G., and Grandgenett, D. P., J.haps, for these integrases, the conformations of the com-
Virol. 66, 6257–6263 (1992).plexes with purified integrase and preintegration com-
18. Ji, H., Moore, D. P., Blomberg, M. A., Braiterman, L. T., Voytas,plexes are more similar than they are for HIV. This might
D. F., Natsoulis, G., and Boeke, J. D., Cell 73, 1–20 (1993).
help to explain the surprising differences in the integra- 19. Katz, R. A., Merkel, G., Kulkosky, J., Leis, J., and Skalka, A. M., Cell
tion-site preferences of purified HIV integrase and prein- 63, 87–95 (1990).
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5319–5327 (1989).tection of 5-bp staggers in HIV integration sites reported
21. Kitamura, Y., Lee, Y. M., and Coffin, J. M., Proc. Natl. Acad. Sci.here may serve as a useful assay in future studies for
USA 89, 5532–5536 (1992).
the correct assembly of preintegration complexes from 22. Leavitt, A. D., Rose, R. B., and Varmus, H. E., J. Virol. 66, 2359–
purified components. 2368 (1992).
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